Published in Blood Weekly, September 7th, 2006
Study 1: Allogeneic stem cell transplantation using umbilical cord blood or matched-sibling donors is comparable in adults with high-risk advanced Hodgkin's lymphoma.
"We compared the safety and efficacy of allogeneic stem cell transplantation (allo-SCT) after reduced-intensity conditioning using either unrelated umbilical cord blood (UCB) donors or matched-sibling donors (MSDs) for 21 adults at high risk with advanced Hodgkin lymphoma (UCB, n=9; MSD, n=12).
"Both groups were comparable except for younger age in the UCB cohort (median, 28...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
Source: Blood Weekly (2006-09-07)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.